托法替布与心血管结局风险:类风湿关节炎常规诊疗患者中托法替布安全性(STAR-RA)研究结果
该研究利用三个美国理赔数据库构建真实世界证据队列和模拟ORAL Surveillance入排标准的RCT重复队列,比较托法替布与TNF抑制剂的心血管复合结局风险。真实世界证据队列102263例中12852例(12.6%)起始托法替布,合并加权HR为1.01(0.83至1.23);RCT重复队列HR为1.24(0.90至1.69),与ORAL Surveillance结果(HR 1.33,95%CI 0.91至1.94)接近。作者结论为真实世界未发现托法替布增加心血管结局风险证据,但在具有心血管危险因素的患者中托法替布与心血管结局风险增加相关,尽管未达统计学显著。
要点
- 真实世界证据队列中托法替布对比TNF抑制剂的心血管复合结局合并加权HR为1.01(0.83至1.23)。
- RCT重复队列HR为1.24(0.90至1.69),与ORAL Surveillance的HR 1.33(0.91至1.94)接近。
- 作者结论为真实世界未发现风险增加证据,但心血管危险因素患者中风险增加且未达统计学显著。
核心结论
- 真实世界诊疗的RA患者中未发现托法替布增加心血管结局风险的证据;但在具有心血管危险因素的患者中,托法替布与心血管结局风险增加相关,尽管未达统计学显著。
研究设计与样本
- 利用Optum Clinformatics(2012-2020)、IBM MarketScan(2012-2018)和Medicare(A、B、D部分,2012-2017)去标识理赔数据构建两个RA起始托法替布或TNF抑制剂治疗的队列。
- 真实世界证据队列由常规诊疗患者组成;RCT重复队列模拟ORAL Surveillance试验的纳入和排除标准以校准结果。
- 采用倾向评分精细分层加权的Cox比例风险模型估计HR和95%CI,校正76个潜在混杂因素。
- 各数据库效应估计采用逆方差加权固定效应模型合并。
主要发现
- 真实世界证据队列共识别102263例患者,其中12852例(12.6%)起始托法替布。
- 真实世界证据队列中托法替布对比TNF抑制剂的合并加权HR(95%CI)为1.01(0.83至1.23)。
- RCT重复队列中托法替布对比TNF抑制剂的合并加权HR(95%CI)为1.24(0.90至1.69)。
- RCT重复队列结果与ORAL Surveillance试验结果(HR 1.33,95%CI 0.91至1.94)高度一致。
关键数值与推荐
- 主要结局为心肌梗死和卒中的复合结局。
- 真实世界证据队列合并加权HR 1.01(95%CI 0.83至1.23),比较托法替布与TNF抑制剂。
- RCT重复队列合并加权HR 1.24(95%CI 0.90至1.69),比较托法替布与TNF抑制剂。
- ORAL Surveillance试验HR 1.33(95%CI 0.91至1.94)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Recent results from 'ORAL Surveillance' trial have raised concerns regarding the cardiovascular safety of tofacitinib in patients with rheumatoid arthritis (RA). We further examined this safety concern in the real-world setting. METHODS: We created two cohorts of patients with RA initiating treatment with tofacitinib or tumour necrosis factor inhibitors (TNFI) using deidentified data from Optum Clinformatics (2012-2020), IBM MarketScan (2012-2018) and Medicare (parts A, B and D, 2012-2017) claims databases: (1) A 'real-world evidence (RWE) cohort' consisting of routine care patients and (2) A 'randomised controlled trial (RCT)-duplicate cohort' mimicking inclusion and exclusion criteria of the ORAL surveillance trial to calibrate results against the trial findings. Cox proportional hazards models with propensity score fine stratification weighting were used to estimate HR and 95% CIs for composite outcome of myocardial infarction and stroke and accounting for 76 potential confounders. Database-specific effect estimates were pooled using fixed effects models with inverse-variance weighting. RESULTS: In the RWE cohort, 102 263 patients were identified of whom 12 852 (12.6%) initiated tofacitinib. The pooled weighted HR (95% CI) comparing tofacitinib with TNFI was 1.01 (0.83 to 1.23) in RWE cohort and 1.24 (0.90 to 1.69) in RCT-duplicate cohort which aligned closely with ORAL-surveillance results (HR: 1.33, 95% CI 0.91 to 1.94). CONCLUSIONS: We did not find evidence for an increased risk of cardiovascular outcomes with tofacitinib in patients with RA treated in the real-world setting; however, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors. TRIAL REGISTRATION NUMBER: NCT04772248.
引用
- Khosrow-Khavar F, Kim SC, Lee H, et al. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022. PMID: 35027405. doi:10.1136/annrheumdis-2021-221915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。